ACADIA Pharmaceuticals (ACAD) Expected to Announce Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $239.32 million for the quarter.

ACADIA Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ:ACAD opened at $14.32 on Wednesday. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $20.68. The company has a market capitalization of $2.39 billion, a P/E ratio of 18.29 and a beta of 0.54. The stock's fifty day simple moving average is $16.42 and its 200-day simple moving average is $16.93.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ACAD shares. HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. UBS Group cut their price target on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a report on Monday. StockNews.com raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, March 8th. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 8th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $23.87.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This trade represents a 21.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Mark C. Schneyer sold 2,708 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $40,132.56. Following the completion of the sale, the executive vice president now owns 59,456 shares of the company's stock, valued at approximately $881,137.92. The trade was a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 14,169 shares of company stock worth $242,686. Corporate insiders own 28.30% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.